Evotec SE's book value per share for the quarter that ended in Mar. 2026 was CHF3.59.
During the past 12 months, Evotec SE's average Book Value Per Share Growth Rate was -23.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -11.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -2.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 16.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Evotec SE was 39.90% per year. The lowest was -25.60% per year. And the median was 5.50% per year.
Evotec SE's current price is CHF4.50. Its book value per share for the quarter that ended in Mar. 2026 was CHF3.59. Hence, today's PB Ratio of Evotec SE is 1.25.
During the past 13 years, the highest P/B Ratio of Evotec SE was 9.81. The lowest was 0.91. And the median was 4.63.
Evotec SE (XSWX:EVT) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Evotec SE Book Value per Share Related Terms
Evotec SE Book Value per Share Historical Data
* Premium members only.
The historical data trend for Evotec SE's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:EVT vs ZTS, UTHR, VTRS: Book Value per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's PB Ratio distribution charts can be found below:
* The bar in red indicates where Evotec SE's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (XSWX:EVT) has a Book Value per Share of CHF3.59 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Evotec SE and its competitors.
Is Evotec SE's Book Value per Share too high?
Evotec SE's current Book Value per Share is CHF3.59. Overall, Evotec SE has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Book Value per Share compare to ZTS and UTHR?
Evotec SE's Book Value per Share of CHF3.59 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Evotec SE and its competitors. Evotec SE's current Book Value per Share is CHF3.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (XSWX:EVT) is currently considered Possible Value Trap. The stock's GF Value™ is CHF6.99, compared to a current price of CHF4.50 — trading 35.6% below its estimated fair value. The current Book Value per Share is CHF3.59. Evotec SE's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current Book Value per Share is CHF3.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (XSWX:EVT) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of CHF4.50 is trading 35.6% below its estimated GF Value™ of CHF6.99.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for XSWX:EVT:
Book Value per Share: CHF3.59
GF Value™: CHF6.99 vs. price of CHF4.50 (35.6% below fair value)
No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
68GF Score
Get the complete analysis for XSWX:EVT
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EVT has been successfully added to your 
